{"id":"NCT02300311","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy and Safety of Finalgon® Cream Multiple Doses in Acute Low Back Pain","officialTitle":"A Multinational, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of Finalgon® Cream (1.08% Nicoboxil/ 0.17% Nonivamide) in the Treatment of Acute Low Back Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2014-11-25","resultsPosted":"2016-09-13","lastUpdate":"2016-09-13"},"enrollment":138,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Low Back Pain"],"interventions":[{"type":"DRUG","name":"nonivamide + nicoboxil (Finalgon cream)","otherNames":[]},{"type":"DRUG","name":"placebo matching nonivamide + nicoboxil (Finalgon cream)","otherNames":[]}],"arms":[{"label":"nonivamide + nicoboxil (Finalgon cream)","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate efficacy of Finalgon® cream (1.08% Nicoboxil/ 0.17% Nonivamide) versus placebo in patients with acute low back pain. To investigate the safety and tolerability of repeated use of Finalgon® cream (1.08% Nicoboxil/ 0.17% Nonivamide).","primaryOutcome":{"measure":"Pain Intensity Difference (PID) From Pre-dose Baseline to 8h After the First Trial Medication Application (PID8h)","timeFrame":"Baseline and 8 hours after trial medication application","effectByArm":[{"arm":"Placebo","deltaMin":-0.98,"sd":0.215},{"arm":"Finalgon® Cream (Nicoboxil/ Nonivamide)","deltaMin":-2.82,"sd":0.221}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["Russia","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":69},"commonTop":[]}}